Advancement of Cancer-associated Fibroblasts in Oral Squamous Cell Carcinoma

doi:10.13701/j.cnki.kqyxyj.2020.04.001

Abstract

Abstract: Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the head and neck, and cancer-associated fibroblasts (CAFs) are the most important stromal cells in the tumor microenvironment as similar with other malignancies. CAFs were critically involved in the proliferation, metastasis, immune tolerance, and treatment resistance of tumor cells. This paper aims to summarize the recent progress of CAFs in OSCC and its enlightenment for clinical treatment. Targeting CAFs for therapeutic intervention and breaking the essential microenvironment barrier to suppress the growth and migration of tumor cells, effectively block angiogenesis,and enhance immune responses may provide a novel insight and strategies for the adjuvant therapy of OSCC.

Key words: oral squamous cell carcinoma, cancer-associated fibroblasts, targeted therapy

HU Qingang, ZHAO Xingxing. Advancement of Cancer-associated Fibroblasts in Oral Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2020, 36(4): 309-313.

References

[1] Gunaydin G, Kesikli SA, Guc D. Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset[J]. Oncoimmunology, 2015, 4(9):e1034918.
[2] Zeisberg EM, Potenta S, Xie L, et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts[J]. Cancer Res, 2007, 67(21):10123-10128.
[3] Nie L, Lyros O, Medda R, et al. Endothelial-mesenchymal transition in normal human esophageal endothelial cells cocultured with esophageal adenocarcinoma cells: role of IL-1beta and TGF-beta2[J]. Am J Physiol Cell Physiol, 2014, 307(9):C859-C877.
[4] Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing[J]. Nat Commun, 2018, 9(1):5150.
[5]Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer[J]. J Exp Med, 2017, 214(3):579-596.
[6] Li H, Zhang J, Chen SW, et al. Cancer-associated fibroblasts provide a suitable microenvironment for tumor development and progression in oral tongue squamous cancer[J]. J Transl Med, 2015, 13:198.
[7] Marsh D, Suchak K, Moutasim KA, et al. Stromal features are predictive of disease mortality in oral cancer patients[J]. J Pathol, 2011, 223(4):470-481.
[8] Melling GE, Flannery SE, Abidin SA, et al. A miRNA-145/TGF-beta1 negative feedback loop regulates the cancer-associated fibroblast phenotype[J]. Carcinogenesis, 2018, 39(6):798-807.
[9] Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium[J]. Cancer Res, 1999, 59(19):5002-5011.
[10] Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice[J]. Proc Natl Acad Sci U S A, 2004, 101(14):4966-4971.
[11] Sobral LM, Bufalino A, Lopes MA, et al. Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A[J]. Oral Oncol, 2011, 47(9):840-846.
[12] Zhou B, Zhuang XM, Wang YY, et al. Tumor necrosis factor alpha induces myofibroblast differentiation in human tongue cancer and promotes invasiveness and angiogenesis via secretion of stromal cell-derived factor-1[J]. Oral Oncol, 2015, 51(12):1095-1102.
[13] Mirkeshavarz M, Ganjibakhsh M, Aminishakib P, et al. Interleukin-6 secreted by oral cancer- associated fibroblast accelerated VEGF expression in tumor and stroma cells[J]. Cell Mol Biol (Noisy-le-grand), 2017, 63(10):131-136.
[14] Yamamura Y, Asai N, Enomoto A, et al. Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression[J]. Cancer Res, 2015, 75(5):813-823.
[15] Li YY, Tao YW, Gao S, et al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p[J]. EBioMedicine, 2018, 36:209-220.
[16] Ding L, Ren J, Zhang D, et al. A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF/interleukin-33[J]. Carcinogenesis, 2018, 39(3):397-406.
[17] O'Connell JT, Sugimoto H, Cooke VG, et al. VEGF-A and Tenascin-C produced by S100A4⁺ stromal cells are important for metastatic colonization[J]. Proc Natl Acad Sci U S A, 2011, 108(38):16002-16007.
[18] Dourado MR, Guerra ENS, Salo T, et al. Prognostic value of the immunohistochemical detection of cancer-associated fibroblasts in oral cancer: A systematic review and meta-analysis[J]. J Oral Pathol Med, 2018, 47(5):443-453.
[19] Chaudhry SI, Hooper S, Nye E, et al. Autocrine IL-1beta-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNFalpha signalling to carcinoma-associated fibroblasts[J]. Oncogene, 2013, 32(6):747-758.
[20] Wang Y, Jing Y, Ding L, et al. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway[J]. J Exp Clin Cancer Res, 2019, 38(1):274.
[21] Kondoh N, Mizuno-Kamiya M, Takayama E, et al. Perspectives of immune suppression in the tumor microenvironment promoting oral malignancy[J]. Open Dent J, 2018, 12:455-465.
[22] Takahashi H, Sakakura K, Kudo T, et al. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages[J]. Oncotarget, 2017, 8(5):8633-8647.
[23] Takahashi H, Sakakura K, Kawabata-Iwakawa R, et al. Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma[J]. Cancer Immunol Immunother, 2015, 64(11):1407-1417.
[24] Johansson AC, Ansell A, Jerhammar F, et al. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells[J]. Mol Cancer Res, 2012, 10(9):1158-1168.
[25] Qin X, Guo H, Wang X, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5[J]. Genome Biol, 2019, 20(1):12.
[26] Zhang D, Ding L, Li Y, et al. Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells[J]. Sci Rep, 2017, 7(1):16231.
[27] Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival[J]. Cancer Cell, 2014, 25(6):719-734.
[28] Zhao X, Ding L, Lu Z, et al. Diminished CD68⁺ cancer-associated fibroblasts subset induces Tregs infiltration and predicts poor prognosis of oral squamous cell carcinoma patients[J]. Am J Pathol, 2020, 190(4):886-899.
[29] D'Arcangelo E, Wu NC, Cadavid JL, et al. The life cycle of cancer-associated fibroblasts within the tumour stroma and its importance in disease outcome[J]. Br J Cancer, 2020, 122(7):931-942.
[30] Duperret EK, Trautz A, Ammons D, et al. Alteration of the tumor stroma using a consensus DNA vaccine targeting fibroblast activation protein (FAP) synergizes with antitumor vaccine therapy in mice[J]. Clin Cancer Res, 2018, 24(5):1190-1201.
[31] Sweeny L, Liu Z, Lancaster W, et al. Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor[J]. Laryngoscope, 2012, 122(7):1539-1544.
[32] Mediavilla-Varela M, Boateng K, Noyes D, et al. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts[J]. BMC Cancer, 2016, 16:176.
[33] Albrengues J, Bertero T, Grasset E, et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts[J]. Nat Commun, 2015, 6:10204.
[34] Ding L, Ren J, Zhang D, et al. The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatin-based chemoimmunotherapy while reducing side effects[J]. Mol Cancer Ther, 2017, 16(6):1068-1079.
[35] Mersmann M, Schmidt A, Rippmann JF, et al. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas[J]. Int J Cancer, 2001, 92(2):240-248.